Structured surveillance of patients with peripheral arterial occlusive disease after peripheral vascular interventions

Vasa - Journal of Vascular Diseases

Volumn 38, Issue 4, 2009, Pages 302-315

  Weiss, Norbert ^a   Bergert, H ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Anticoagulant therapy; Antiplatelet therapy; Antithrombotic therapy; Bypass surgery; Bypass surveillance; Cardiovascular risk factors; Endovascular intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RAMIPRIL; TICLOPIDINE; VALSARTAN;

ALLOGRAFT; ANTICOAGULATION; ARTERY DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; ENDARTERECTOMY; ENDOVASCULAR SURGERY; EVIDENCE BASED PRACTICE; FOLLOW UP; GLYCEMIC CONTROL; GRAFT PATENCY; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MORTALITY; PATIENT MONITORING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; STENT; THROMBOSIS; VASCULAR SURGERY; VEIN GRAFT;

ALGORITHMS; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; CONSTRICTION, PATHOLOGIC; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR SURGICAL PROCEDURES;

EID: 73149096237     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.38.4.302     Document Type: Review

References (81)

1. Abbruzzese TA, Havens J, Belkin M, Donaldson MC, Whittemore AD, Liao JK, Conte MS. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2006; 39: 1178-85.
2. Anonymus. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
3. Anonymus. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-51.
4. Anonymus. CASPAR: Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral Arterial Disease. National Institutes of Health, Clinical Trials. gov; 2005: NCT00174759.
5. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
6. Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fach gesellschaften. Medikamentöse Therapie nach gefäßchirur gischen Operationen und endo vaskulären Interventionen. Leit linien der Deutschen Gesellschaft für Gefäßchirurgie (vaskuläre und endovaskuläre Chirurgie) (DGG). 2008 [cited 19.03.2009]; Available from: http://www.uni-duesseldorf.de/AWMF/11/ 004-030.htm
7. Arfvidsson B, Lundgren F, Drott C, Schersten T, Lundholm K. Infl uence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159: 556-60.
8. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001; 87: 1284-6.
9. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92: 711-2.
10. Bandyk DF. Surveillance after lower extremity arterial bypass. Perspect Vasc Surg Endovasc Ther 2007; 19: 376-83; discussion 84-5.
11. Bandyk DF, Chauvapun JP. Duplex ultrasound surveillance can be worthwhile after arterial intervention. Perspect Vasc Surg Endovasc Ther 2007; 19: 354-9; discussion 60-1.
12. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
13. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
14. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Jama 2006; 295: 180-9.
15. Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2008: CD000535.
16. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL, Bandyk DF. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. J Vasc Surg 2007; 46: 1160-6.
17. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. Bmj 2003; 326: 584-8.
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
20. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). Circulation 2005; 112: 1985-91.
21. Davies AH, Magee TR, Tennant SGW, Baird RN, Horrocks M. Criteria for identification of the "at risk" infrainguinal bypass graft. Eur J Vasc Surg 1994; 8: 315-9.
22. Dick F, Diehm N, Galimanis A, Husmann M, Schmidli J, Baumgartner I. Surgical or endovascular revascularization in patients with critical limb ischemia: infl uence of diabetes mellitus on clinical outcome. J Vasc Surg 2007; 45: 751-61.
23. Diehm C, Lange S, Darius H, Pittrow D, von Stritzky B, Tepohl G, Haberl RL, Allenberg JR, Dasch B, Trampisch HJ. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27: 1743-9.
24. Dorffler-Melly J, Buller HR, Koopman MM, Prins MH. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003: CD000536.
25. Dorffler-Melly J, Koopman MM, Adam DJ, Buller HR, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003: CD000535.
26. Dorffler-Melly J, Koopman MM, Prins MH, Buller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005: CD002071.
27. Engelhardt M, Bruijnen H, Scharmer C, Wohlgemuth WA, Willy C, Wolfle KD. Prospective 2-years follow-up quality of life study after infrageniculate bypass surgery for limb salvage: lasting improvements only in non-diabetic patients. Eur J Vasc Endovasc Surg 2008; 36: 63-70.
28. Erez G, Leitersdorf E. The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease. Eur J Vasc Endovasc Surg 2007; 33: 192-201.
29. Fares RR, Lansing LS, Gallati CA, Mousa SA. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opin Pharmacother 2008; 9: 377-86.
30. Golledge J, Beattie DK, Greenhalgh RM, Davies AH. Have the results of infrainguinal bypass improved with the widespread utilisation of postoperative surveillance? Eur J Vasc Endovasc Surg 1996; 11: 388-91.
31. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholteop Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-414.
32. Grundy SM, Cleeman JI, Merz CN, Brewer HBJ, Clark LT, Hunninghake DB, Pasternak RC, Smith SCJ, Stone NJ, National Heart L, and Blood Institute, Foundation ACoC, As so ciation AH. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
33. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21: 325-35.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
35. Henke P, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajagopalin S, Upchurch GRJ, Stanley JC, Eagle KA. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004; 39: 1474-547.
36. Hindler K, Shaw AD, Samuels J, Fulton S, Collard C, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105: 1260-72.
37. Idu MM, Buth J, Hop WC, Cuypers P, van de Pavoordt ED, Tordoir JM. Factors influencing the development of vein-graft stenosis and their significance for clinical management. Eur J Vasc Endovasc Surg 1999; 17: 15-21.
38. Johnson WC, Williford WO. Benefi ts, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413-21.
39. Kretschmer G, Herbst F, Prager M, Sautner T, Wenzl E, Berlakovich GA, Zekert F, Marosi L, Schemper M. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127: 1112-5.
40. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dörge H, Stamm C, Wassmer G, Wahlers T. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 2008; 29: 1548-59.
41. Mewissen MW, Kinney EV, Bandyk DF, Reifsnyder T, Seabrook GR, Lipchik EO, Towne JB. The role of duplex scanning versus angiography in predicting outcome after balloon angioplasty in the femoropopliteal artery. J Vasc Surg 1992; 15: 860-5.
42. Mills JL. Mechanisms of vein graft failure: the location, distribution, and characteristics of lesions that predispose to graft failure. Semin Vasc Surg 1993; 6.
43. Mills JL, Harris EJ, Taylor LM, Jr., Beckett WC, Porter JM. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. J Vasc Surg 1990; 12: 379-86; discussion 87-9.
44. Minion DJ. Commentary on "duplex surveillance of lower extremity endovascular interventions. Perspect Vasc Surg Endovasc Ther 2007; 19: 175.
45. Miura S, Saku K. Which strategy is more effective for the treatment of cardiovascular disease: high-dose angiotensin II type 1 receptor antagonist monotherapy or combination therapy? Am J Cardiovasc Drugs 2008; 8: 88-90.
46. Mofidi R, Kelman J, Berry O, Bennett S, Murie JA, Dawson AR. significance of the early postoperative duplex result in infrainguinal vein bypass surveillance. Eur J Vasc Endovasc Surg 2007; 34: 327-32.
47. Mofidi R, Pandanaboyana S, Flett MM, Nagy J, Griffi ths GD, Stonebridge PA. The value of vein graft surveillance in bypasses performed with smalldiameter vein grafts. Ann Vasc Surg 2009; 23: 17-23.
48. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, Pastore M, Borrello F, Belcastro M, Picchi A, Nami R. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients peripheral vascular disease. Am J Med 2003; 114: 359-64.
49. Moody P, DeCossart LM, Douglas HM, Harris PL. Asymptomatic strictures in femoropopliteal vein grafts. Eur J Vasc Surg 1989; 75: 737-40.
50. Moody P, Gould DA, Harris PL. Vein graft surveillance improves patency in femoropopliteal bypass. Eur J Vasc Surg 1990; 4: 117-21.
51. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E, 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfi eld K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 Suppl 1: S1-75.
52. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17-24.
53. Papanicolaou G, Beach KW, Zierler RE, Strandness DE, Jr. The relationship between arm-ankle pressure difference and peak systolic velocity in patients with stenotic lower extremity vein grafts. Ann Vasc Surg 1995; 9: 554-60.
54. Pedersen M, Kjekhusj TR, Pyorala K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study. Am J Cardiol 1998; 81: 333-5.
55. Perler BA. The Effect of Statin Medications on Perioperative and Long-Term Outcomes Following Carotid Endarterectomy or Stenting. Seminars in Vascular Surgery 2007; 20: 252-8.
56. Peters S. Comparison of efficacy of low- (80 mg/day) and high-(160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs 2008; 8: 83-7.
57. Rice TW, Lumsden AB. Optimal medical management of peripheral arterial disease. Vasc Endovascular Surg 2006; 40: 312-27.
58. Samson RH. The role of statin drugs in the management of the peripheral vascular patient. Vasc Endovascular Surg 2008; 42: 352-66.
59. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, Seeger JM. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28: 446-57.
60. Sayers RD, Raptis S, Berce M, Miller JH. Long-term results of femorotibil bypass with vein or polytetrafl uoroethylene. Br J Surg 1998; 85: 934-8.
61. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are inde pendently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008; 47: 774-81.
62. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Ballon angioplasty versus implantation of nitinol stents in the superfi cial femoral artery. N Engl J Med 2006; 354: 1879-88.
63. Schindler C, Mueller A, Bramlage P, Boecking W, Kirch W, Schweizer J. Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proff-of-concept study. Angiology 2007; 58: 710-6.
64. Schneider E, Brunner U, Bollinger A. Medical treatment for preventing recurrence after femoro-popliteal arterial reconstruction. Angio 1979; 2: 73-7.
65. Schweizer J, Muller A, Forkmann L, Hellner G, Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology 2001; 52: 659-69.
66. Shames ML. Duplex surveillance of lower extremity endovascular interventions. Perspect Vasc Surg Endovasc Ther 2007; 19: 370-4; discussion 5.
67. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130-9.
68. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 815S-43S.
69. Spijkerboer AM, Nass PC, de Valois JC, van der Graaf Y, Eikelboom BC, Mali WP. Evaluation of femoropopliteal arteries with duplex ultrasound after angioplasty: can we predict results at one year? Eur J Endovasc Surg 1996; 12: 418-2.
70. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Sr., Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. Jama 2007; 297: 1197-206.
71. Stoyioglou A, Jaff MR. Medical treatment of peripheral arterial disease: A comprehensive review. J Vasc Interv Radiol 2004; 15: 1197-207.
72. Strecker EP, Boos IB, Gottmann D, Vetter S. Clopidogrel plus long-term aspirin after femoropopliteal stenting. The CLAFS project: 1- and 2-year results. Eur Radiol 2004; 14: 302-8.
73. Szilagyi DE, Elliott JP, Hageman JH, Smith RF, Dall'olo CA. Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoro-popliteal operations for atherosclerosis. Ann Surg 1973; 178: 232-46.
74. Tan JY, Shi WH, He J, Zhu L, Wang TP, Yu B. [A clinical trial of using antiplatelet therapy to prevent restenosis following peripheral artery angioplasty and stenting]. Zhonghua Yi Xue Za Zhi 2008; 88: 812-5.
75. Tinder CN, Chavanpun JP, Bandyk DF, Armstrong PA, Back MR, Johnson BL, Shames ML. efficacy of duplex ultrasound surveillance after infrainguinal vein bypass may be enhanced by identification of characteristics predictive of graft stenosis development. J Vasc Surg 2008; 48: 613-8.
76. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
77. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, Bax JJ, van Sambeek MR, Poldermans D. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51: 1588-96.
78. Wilensky R. Angiotensin-receptor blockers: revival of the systemic prevention of restenosis? Cardiovasc Drugs Ther 2003; 17: 63-73.
79. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42: 67-74.
80. Wolfl e KD, Neudert S, Mayer B, Storm G, Bruijnen H, Loeprecht H. [Duplex sonographic monitoring of infra-inguinal arterial reconstructions: can a threatened bypass occlusion be detected by this method?]. Zentralbl Chir 1992; 117: 540-6.
81. Zeymer U, Parhofer KG, Pittrow D, Binz C, Schwertfeger M, Limbourg T, Rother J. Risk factor profi le, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol 2009; 98: 249-56.